Prostate cancer is one of the most common cancer worldwide, where South Sulawesi is included in four provinces with the highest prevalence of prostate cancer in Indonesia. Laboratorium Sentra Patologia Makassar (SDPM) stated that prostate cancer cases continue to rise each year. Androgen receptor (AR) plays a role in the growth and differentiation of male urogenital structures, both under normal and neoplastic conditions, the neoplastic condition is caused by the mechanism of the AR pathway which undergoes changes that continue in the development and progression of prostate lesions, both benign and malignant. Androgen receptors are generally found evenly distributed in the nuclei of glandular and stromal cells in prostate hyperplasia and vary widely in prostate cancer. These inventions show that AR inhibitors are used to treat prostate adenocarcinoma by inhibiting androgen synthesis. Assessment of AR expression can be used in determining therapy and predicting the success of hormonal therapy so that the prognosis of the disease is better. This study is conducted to learn more about AR expression in adenocarcinoma prostate grading. The type of this research is an observational analytical study with cross-sectional methods. Samples are taken based on consecutive sampling of as many as 77 respondents. There is a significant difference between AR expression score and histopathological feature of prostate adenocarcinoma WHO Grup Grade (p<0,001). In conclusion, there is a significant correlation between AR and WHO Grup Grade and could be used as important marker in grading adenocarcinoma prostate progression
 Keywords : Androgen receptor (AR); prostate adenocarcinoma; WHO Grup Grade